Comparison · NCT01468987-sae
LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events. Trial comparisons, record NCT01468987-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01468987-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.114 | 0.0927 | 0.14 | wilson | |
| Risk in group 2 | 0.0931 | 0.0734 | 0.117 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0213 | -0.0112 | 0.0538 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.898 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 1.26 | 0.887 | 1.78 | log | |
| Number needed to harm, for one more participant with a serious adverse event on LY2605541 + Insulin Lispro than on Insulin Glargine + Insulin Lispro | 47 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LY2605541 + Insulin Lispro | Participant-specific doses of LY2605541 were administered SC once daily at bedtime for 26 weeks.~Participant-specific doses of Insulin Lispro were administered SC for preprandial and supplemental doses for 26 weeks. | 79 | 691 | EG000 |
| Group 2 | Insulin Glargine + Insulin Lispro | Participant-specific doses of Insulin Glargine were administered SC once daily at bedtime for 26 weeks.~Participant-specific doses of Insulin Lispro were administered SC for preprandial and supplemental doses for 26 weeks. | 63 | 677 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Study in Participants With Type 2 Diabetes Mellitus
- NCT number
- NCT01468987
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2605541, Insulin Glargine, Insulin Lispro
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2018-04-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01468987?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01468987-sae